Annovis Bio (NYSE:ANVS – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on ...

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has received a notice from the New York Stock Exchange (NYSE) regarding its ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant ...

As set forth in the Notice, as of March 25, 2025, the 30 trading-day average market capitalization of the Company was approximately $37.9 million and the Company’s last reported stockholders’ equity ...

Annovis Bio (ANVS) announced that it received notice from the NYSE that it is no longer in compliance with the NYSE continued listing standards ...

Annovis’ cash and cash equivalents totaled $10.6M as of December 31, 2024, compared to $5.8M as of December 31, 2023. The company estimates ...

The AD/PD™ 2025 conference brings together the brightest minds in the field in order to share the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical ...

Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, Ratings reports. One research ...

MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...